Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 1;18(13):4984–5000. doi: 10.7150/ijbs.75284

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

The design and process of our study are shown in the flow chart. In the present study, We first identified differentially expressed genes in CTC and in situ tumors based on dataset GSE74639 and TCGA-LUAD dataset in metastatic patients versus non-metastatic patients, and obtained methylation probe information of differential genes to identify differentially methylated driver genes. Then, A risk model was constructed which comprised of three DMGs in CTCs of LUAD. Next, we systematically assessed the prognostic model's stability and accuracy in both the external validation and the training cohorts. The biological functions, TME, and genomic variations in the prognostic model were evaluated in detail. At last, the value of the prognostic model was determined and its clinical applicability in chemotherapy and immunotherapy of LUAD was evaluated.